COVID-19(10) lung cancer(10) Cancer(8) SARS-CoV-2(7) Patient(7) pandemic(6) stage III(5) receiving(5) patients treated(5) analysed(5) management(4) Treatment(4) Immunotherapy(4) NSCLC.(3) approved(3) COVID-19 pandemic(3) Autoimmune disease(3) adjuvant(3) two groups(3) observé(3) treated(3) Safety(3) Toxicity(3) clinical(3) blood tests(3) implication(3) hospital(3) Retrospective study(3) Adjuvant durvalumab(3) toxicities(3)